Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly 610,000 people expected to die from the disease, according to the National Cancer Institute. Fortunately, several recent cancer treatments show considerable promise. Among them is Chimeric Antigen Receptor (CAR) T cell […]Continue Reading ...
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-positive breast cancer patients with brain metastases – is now […]Continue Reading ...
Kidney disease often lacks symptoms until it is at an advanced stage. Credit: Kristoffer Lindskov Hansen, Michael Bachmann Nielsen and Caroline Ewertsen, licensed under CC BY 4.0 Recent advances in kidney research have yielded dramatic headlines touting scientists’ ability to grow kidneys in the lab. But some experts worry that hype about tissue engineering is […]Continue Reading ...
Loyola University Chicago and Loyola Medicine have announced plans to become the first Chicago center to produce cancer-fighting CAR-T cells to treat leukemia and lymphoma. CAR-T cell therapy has been shown to be remarkably effective in treating cancer patients who have failed standard treatments, but it is expensive and can cause severe side effects. Loyola […]Continue Reading ...
August 21, 2018 CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling anti-cancer responses have not been thoroughly examined. Understanding these pathways is important for designing future generations of […]Continue Reading ...
August 14, 2018 University Hospitals Seidman Cancer Center launched a new clinical trial for CAR-T, joining a select group of hospitals offering the therapy and a smaller group of hospitals manufacturing the CAR-T cells. CAR-T therapy has been called a “living drug” and is part of a rapidly emerging immunotherapy approach called adoptive cell transfer […]Continue Reading ...
WEDNESDAY, July 25, 2018 — You know that wearing seat belts and putting kids in appropriate car seats can save lives, but are you doing all you can to make your car a safe environment for little ones? Hundreds of thousands of car seats are recalled for safety defects every year, with more than 6 […]Continue Reading ...
June 25, 2018 AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors. This collaboration broadens AbbVie’s oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments […]Continue Reading ...
Credit: CC0 Public Domain Today, a new blood cancer treatment was approved for use on the NHS in England. And in early September, NHS England announced another, similar treatment will be available to some children and young people with a different type of blood cancer. As with any new drug approval, these announcements are great […]Continue Reading ...
Researchers at the University of Pennsylvania have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy. Image Credit: Juan Gaertner / Shutterstock The study, which was recently published in the journal Nature Medicine, has explained how a single leukemic cell became resistant […]Continue Reading ...
Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is transforming the treatment of solid and hematological cancer by developing the […]Continue Reading ...
August 15, 2018 Scientists at Memorial Sloan Kettering Cancer Center (MSK) announced that they have built a new model of genetically engineered immune cells in mice that may allow them to fight solid tumors. The new cells combine two of the most promising types of immunotherapy into one sleek package: chimeric antigen receptor (CAR) T […]Continue Reading ...
August 7, 2018 Seattle Children’s has opened a chimeric antigen receptor (CAR) T-cell immunotherapy trial for children and young adults with relapsed or refractory non-central nervous system EGFR-expressing solid tumors. In the phase 1 trial, STRIvE-01, cancer-fighting CAR T cells will target the EGFR protein expressed in many childhood sarcoma, kidney and neuroblastoma tumors. Solid […]Continue Reading ...
By Dr Ananya Mandal, MDJuly 9, 2018 Long drives and long car journeys can make a person sleepy. While driving this is one of the commonest reasons for accidents with one in five accidents occurring due to sleepiness or fatigue behind the wheels. Lead author, PhD researcher Neng Zhang, in the virtual simulator. A team […]Continue Reading ...
Joseph A. Fraietta, Ph.D. (left) and J. Joseph Melenhorst, Ph.D. (right) Credit: Penn Medicine The doctors who have spent years studying the case call it “a series of fortunate events.” What began as a remarkable response to chimeric antigen receptor (CAR) T cell therapy is now providing evidence about the human genome and immune response […]Continue Reading ...
- Biologists uncover novel genetic control of lipid maintenance and its potential connection to lifespan
- Warmer winters may set scene for higher rates of violent crimes
- Acacia Pharma Resubmits Barhemsys New Drug Application
- PDL1 (Immunotherapy) Tests: MedlinePlus Lab Test Information
- Transforming pregnancy research with a smartphone app
- Stanford Medicine magazine explores how digital technology is changing health care
- New report calls for greater awareness and emphasis on scale and impact of atrial fibrillation
- In throes of turkey salmonella outbreak, don’t invite illness to your table
- UK health policies should be redesigned to become more accessible for men
- Short Interpregnancy Intervals Tied to Adverse Outcome Risk
- New mothers’ breastfeeding pain can affect infant health
- Stanford Medicine magazine reports on ways digital technology is transforming health care | News Center
- Human drugs alter cricket personality
- Insilico Medicine to introduce ‘Cure a disease in a year’ program at Biodata World Congress 2018
- Experts debate over whether gut or brain is more important in regulating appetite
- Playing on fear and fun, hospitals follow pharma in direct-to-consumer advertising
- 2PG Company receives grant to develop sensitive, low-cost molecular diagnostic tests for tuberculosis
- Low-Carb Diets May Work By Boosting Calorie Burn
- Key molecule responsible for learning and memory discovered
- New blood test developed for early diagnosis of ovarian cancer